



1605.1#

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Stamm et al**

Application No. **09/899,026**

Group Art Unit: **1615**

Filed: **July 6, 2001**

Examiner: **H. Sheikh**

For: **FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT**

Attorney Docket No: 107664.115US3

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Transmittal Letter

Submitted herewith for appropriate consideration by the US Patent Office are the following documents:

1. Response and Amendment under 37 CFR § 1.111.
2. Petition for Extension of Time.
3. Declaration under 37 CFR § 1.132 by Philippe Réginault.
4. Information Disclosure Statement, PTO-1449 Form, and attachments (including Declaration under 37 CFR § 1.132 by Pascale Blouquin).

The Commissioner is authorized to charge the fee of **\$1200** (including \$180 for the Information Disclosure Statement and \$1020 for a three month extension of time) to Deposit Account No. 08-0219. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account No. 08-0219.

Respectfully submitted,

Edward D. Grieff
Registration No. 38,898

Date: February 23, 2005
WILMER CUTLER PICKERING HALE AND DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: 202-942-8453